2023年ASCO

癸卯年首场泌尿男生殖系肿瘤的国际大秀——2023年美国临床肿瘤学会（ASCO）泌尿男生殖系肿瘤研讨会（ASCO-GU 2023）将于当地时间2月16~18日在美国旧金山举行。在尿路上皮癌领域，阿替利珠单抗单药或联合化疗用于mUC一线治疗的IMvigor130研究将报道最终OS结果，KEYNOTE-057研究则将探讨帕博利珠单抗用于卡介苗无应答高危NMIBC；此外还有多项值得关注的研究入围快速摘要环节。

Oral Abstract Session B: Urothelial Carcinoma

摘要号：LBA440

Atezolizumab (atezo) platinum/gemcitabine (plt/gem) vs placebo plt/gem for first-line (1L) treatment (tx) of locally advanced or metastatic urothelial carcinoma (mUC): Final OS from the randomized Phase 3 IMvigor130 study.

阿替利珠单抗（atezo） ＋铂类/吉西他滨（plt/gem）对比安慰剂＋plt/gem用于局部晚期或转移性尿路上皮癌（mUC）一线（1L）治疗（tx）：随机3期IMvigor130研究的最终OS结果。

摘要号：LBA441

Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.

阿替利珠单抗（atezo）单药治疗对比化疗（chemo）用于未经治疗局部晚期或转移性尿路上皮癌（mUC）的3期IMvigor130研究最终总生存期（OS）分析。

摘要号：LBA442

Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial.

帕博利珠单抗单药治疗用于卡介苗（BCG）无应答的高风险非肌层浸润性膀胱癌（HR NMIBC）患者：2期KEYNOTE-057试验队列B结果。

摘要号：LBA443

Extended follow-up results from the CheckMate 274 trial.

CheckMate 274试验的长期随访结果

Rapid Abstract Session: Urothelial Carcinoma

摘要号：LBA445

Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non–muscle-invasive bladder cancer: A prospective study.

非肌层浸润性膀胱癌患者在二次电切前采用尿液细胞游离DNA（ctDNA）进行微小残留病灶（MRD）监测：一项回顾性研究

摘要号：446

Randomised phase II trial of adaptive image guided radiotherapy in muscle invasive bladder cancer: Late toxicity and cancer outcomes.

图像引导放疗（IGRT）用于肌层浸润性膀胱癌的随机II期试验：远期毒性和癌症结局。

摘要号：447

Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC).

HCRN GU 16-257的共同主要终点分析：吉西他滨、顺铂联合纳武利尤单抗用于肌层浸润性膀胱癌（MIBC）选择性保膀胱患者的2期研究。

摘要号：448

HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer.

HCRN GU14-188：帕博利珠单抗联合化疗用于T2-4aN0M0尿路上皮癌新辅助治疗的Ib/II期研究

摘要号：449

Benefit of whole-pelvis radiation for patients with muscle-invasive bladder cancer: An inverse probability treatment-weighted analysis.

全骨盆放疗用于肌层浸润性膀胱癌患者治疗的获益：一项逆概率治疗-加权分析。

摘要号：520

Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.

戈沙妥珠单抗（SG）用于检查点抑制剂（CPI）治疗进展、铂类（PT）不耐受的转移性尿路上皮癌（mUC）患者的2期TROPHY-U-01研究队列2初步分析。